Prebeta-HDL generation and improved HDL functionality are distinguishing
TSX Exchange Symbol: RVX
NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.
Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We continue to be excited about the data that is being generated for RVX-208. It is important that our colleagues have access to this promising data which is why we have presented at this prominent conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in prebeta-HDL particles, which improve HDL's ability to mediate cholesterol efflux."
"Today we presented interesting and consistent data from African Green monkey studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of Resverlogix. "The pharmacodynamic data from human healthy volunteers of which the majority had low HDL demonstrated that we have seen significant increases in ApoA-I production and HDL functionality, consistent with previous findings in the African Green monkey studies. Further investigation of the effect of RVX-208 on the HDL metabolic pathway is ongoing in humans and animals to establish the mechanisms of action and therapeutic potential in treating atherosclerotic cardiovascular disease."
During the presentation Dr. Genest reported that in an African Green
monkey study treatment with RVX-208 resulted in a highly
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved